


CP-113818

Cat. No.:	HY-105445
CAS No.:	135025-12-6
Molecular Formula:	C ₂₄ H ₄₂ N ₂ OS ₃
Molecular Weight:	470.8
Target:	Acyltransferase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CP-113818 is a potent cholesterol acyltransferase (ACAT) inhibitor. CP-113818 can be used for the research of Alzheimer's disease ^[1] .								
In Vitro	CP-113818 inhibits A β production in cell-based experiments ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>CP-113818 (0-7.1 mg/kg/day) markedly reduces amyloid pathology in a mouse model of Alzheimer's disease^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6, hAPP (human amyloid precursor protein) transgenic mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0, 0.2, 1.6, 3.2, 4.8, and 7.1 mg/kg/day</td> </tr> <tr> <td>Administration:</td> <td>Via implantable slow-release biopolymer pellets, 21 days for nontransgenic mice or 60 days for hAPP mice</td> </tr> <tr> <td>Result:</td> <td> <p>Reduced total cholesterol levels by 29% in the serum, hepatic free cholesterol and cholesteryl-esters were also decreased in a dose-dependent manner by up to 37% and 93%, respectively in the nontransgenic mice.</p> <p>Effectively reduced cholesteryl-ester levels of hAPP mice in the absence of adrenal toxicity, reduced plaque numbers, and decreased amyloid load in a gender-independent manner in hAPP mice.</p> <p>Reduced levels of "insoluble" and soluble Aβ₁₋₄₀ and Aβ₁₋₄₂ in the brains of hAPP transgenic mice.</p> <p>Restored normal spatial learning and memory in female hAPP mice in a morris water maze test.</p> <p>Reduced processing of endogenous APP but not notch or N-cadherin, without directly inhibiting β- and γ-secretase activities or Aβ aggregation in nontransgenic littermates.</p> </td> </tr> </table>	Animal Model:	C57BL/6, hAPP (human amyloid precursor protein) transgenic mice ^[1]	Dosage:	0, 0.2, 1.6, 3.2, 4.8, and 7.1 mg/kg/day	Administration:	Via implantable slow-release biopolymer pellets, 21 days for nontransgenic mice or 60 days for hAPP mice	Result:	<p>Reduced total cholesterol levels by 29% in the serum, hepatic free cholesterol and cholesteryl-esters were also decreased in a dose-dependent manner by up to 37% and 93%, respectively in the nontransgenic mice.</p> <p>Effectively reduced cholesteryl-ester levels of hAPP mice in the absence of adrenal toxicity, reduced plaque numbers, and decreased amyloid load in a gender-independent manner in hAPP mice.</p> <p>Reduced levels of "insoluble" and soluble Aβ₁₋₄₀ and Aβ₁₋₄₂ in the brains of hAPP transgenic mice.</p> <p>Restored normal spatial learning and memory in female hAPP mice in a morris water maze test.</p> <p>Reduced processing of endogenous APP but not notch or N-cadherin, without directly inhibiting β- and γ-secretase activities or Aβ aggregation in nontransgenic littermates.</p>
Animal Model:	C57BL/6, hAPP (human amyloid precursor protein) transgenic mice ^[1]								
Dosage:	0, 0.2, 1.6, 3.2, 4.8, and 7.1 mg/kg/day								
Administration:	Via implantable slow-release biopolymer pellets, 21 days for nontransgenic mice or 60 days for hAPP mice								
Result:	<p>Reduced total cholesterol levels by 29% in the serum, hepatic free cholesterol and cholesteryl-esters were also decreased in a dose-dependent manner by up to 37% and 93%, respectively in the nontransgenic mice.</p> <p>Effectively reduced cholesteryl-ester levels of hAPP mice in the absence of adrenal toxicity, reduced plaque numbers, and decreased amyloid load in a gender-independent manner in hAPP mice.</p> <p>Reduced levels of "insoluble" and soluble Aβ₁₋₄₀ and Aβ₁₋₄₂ in the brains of hAPP transgenic mice.</p> <p>Restored normal spatial learning and memory in female hAPP mice in a morris water maze test.</p> <p>Reduced processing of endogenous APP but not notch or N-cadherin, without directly inhibiting β- and γ-secretase activities or Aβ aggregation in nontransgenic littermates.</p>								

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA